chufangao/CTO huggingface dataset:
Clinical trial NCT04162470: REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.
Official title: An Open-label Extension Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Business Decision
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-03
Primary completion date: 2022-04-07
Completion date: 2022-04-07
Baseline population: Safety Analysis Set (SAF) included all enrolled participants who received any study drug.
Plan to share individual participant data: YES
IPD sharing description: All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD time frame: Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification.
IPD access criteria: Qualified researchers may request access to anonymized patient level data or aggregate study data when Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency \[EMA\], Pharmaceuticals and Medical Devices Agency \[PMDA\], etc) for the product and indication, has the legal authority to share the data, and has made the study results publicly available (eg, scientific publication, scientific conference, clinical trial registry).
Clinical trial NCT02917772: Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Official title: A Phase II Single Arm Clinical Trial of a Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
Acronym: TITAN-RCC
Sponsor: AIO-Studien-gGmbH (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 200.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-31
Primary completion date: 2021-10-31
Completion date: 2022-10-31
Plan to share individual participant data: NO
Clinical trial NCT04729348: Pembrolizumab And Lenvatinib In Leptomeningeal Metastases
Official title: Phase II Trial of Pembrolizumab and Lenvatinib for Leptomeningeal Metastases
Sponsor: Massachusetts General Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Planned interim analysis
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-08
Primary completion date: 2024-01-17
Completion date: 2024-01-17
Plan to share individual participant data: YES
IPD sharing description: The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to Sponsor Investigator or designee. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.
IPD time frame: Data can be shared no earlier than 1 year following the date of publication
IPD access criteria: Contact the Partners Innovations team at http://www.partners.org/innovation
Clinical trial NCT04433767: Depressed Mood Improvement Through Nicotine Dosing 2
Official title: Nicotinic Modulation of the Cognitive Control System in Late-life Depression
Acronym: DepMIND2
Sponsor: Vanderbilt University Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 29.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-15
Primary completion date: 2022-10-07
Completion date: 2022-10-07
Limitations and caveats: Small, open-label study design
Plan to share individual participant data: YES
IPD sharing description: This study will include clinical, cognitive, and neuroimaging data from older depressed subjects. The final dataset will include clinical information about subject psychiatric diagnoses, psychiatric and medical history, cognitive data, and response to transdermal nicotine. We will share data via the National Database for Clinical Trials related to Mental Illness (NDCT). NDCT provides a secure platform for data-sharing allowing for communication of research data, tools, and supporting documents. As required by NDCT, we will obtain a Global Unique Identifier (GUID) for each participant. We will additionally follow NDCT requirements to certify and review data, as well as timeline requirements for data submission and data sharing. Sharing of neuroimaging data will also be facilitated by an XNAT system (xnat.org). XNAT is an open-source informatics software platform that assists in the management and archiving of imaging data.
IPD time frame: Data will be shared according to policies from the NDCT and the NIMH Data Archive (NDA). Descriptive data, outcome measures and analyzed data will be shared will be shared within 4 months of when a publication is accepted. Study data will be shared through the NDCT indefinitely.
IPD access criteria: The NIH will provide access to scientific investigators for research purposes. Qualified researchers who have completed a Data Use Certification and received approval from the NDA Data Access Committee (DAC) may be approved to access broadly shared data. A separate request process exists for access to data in federated sources. Additionally, the DAC and support staff at NIH have access to NDA shared data.
Clinical trial NCT03087708: Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer
Official title: A Randomized, Double-Blind, Placebo-Controlled Pilot Study of an Oral, Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer
Sponsor: Alliance for Clinical Trials in Oncology (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Insufficient accrual
Enrollment: 50.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-10-13
Primary completion date: 2021-01-04
Completion date: 2023-04-01
Clinical trial NCT04891913: SY007 in Patients With Acute Ischemic Stroke
Official title: Phase Ib Clinical Study to Evaluate Safety, Tolerance，Pharmacokinetics and Efficacy of SY-007 After Intravenous Injection in Acute Ischemic Stroke Subjects
Sponsor: Suzhou Yabao Pharmaceutical R&D Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: SUSPENDED 
Why stopped: The sponsor decided to suspend the process
Enrollment: 36.0 (ESTIMATED)
Number of arms: 3.0
Start date: 2023-07-01
Primary completion date: 2023-12-25
Completion date: 2023-12-25
Clinical trial NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension
Official title: Efficacy and Safety of GMRx2 (a Single Pill Combination Containing Telmisartan/Amlodipine/Indapamide) Compared to Dual Combinations for the Treatment of Hypertension
Acronym: GMRx2_ACT
Sponsor: George Medicines PTY Limited (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1385.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-06-26
Primary completion date: 2023-08-01
Completion date: 2023-09-01
Plan to share individual participant data: NO
IPD sharing description: If the sponsor receives a request for study data, then such requests will be reviewed by sponsor following completion of regulatory submissions and review, and with support from members of the GMRX2 steering committee who will advise on the scientific merit and integrity of the proposed analysis.
Clinical trial NCT03382912: Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer
Official title: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Acronym: Cypress 2
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-03-22
Primary completion date: 2019-08-28
Completion date: 2020-03-03
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Yes~Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT03550313: Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants
Official title: A PHASE 2, RANDOMIZED, OPEN-LABEL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH, OR SEPARATELY FROM, 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study vaccinations and blood draws were halted due to adequacy of a smaller dataset and study feasibility issues. It was not based on any safety concerns.
Enrollment: 565.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-01
Primary completion date: 2020-11-05
Completion date: 2020-11-05
Baseline population: The overall safety population included all participants who received at least 1 dose of c7vPnC (in Groups 1 and 2) or Prevnar 13 (in Group 3) and had safety data reported in the study.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT05814523: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)
Official title: A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus
Sponsor: Marinus Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: Business reasons
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2024-03-31
Primary completion date: 2024-08-31
Completion date: 2024-08-31
Plan to share individual participant data: NO
Clinical trial NCT04728646: Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
Official title: Evaluation of Dextenza in Patients With Ocular Graft Vs Host Disease (GVHD) and Effect on Ocular Surface Disease Outcomes.
Sponsor: Massachusetts Eye and Ear Infirmary (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Due to difficulty enrolling subjects whom had not meet the inclusion criteria
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-09-30
Primary completion date: 2021-12-13
Completion date: 2021-12-13
Clinical trial NCT04378244: CORONA: A Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
Official title: CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19
Acronym: CORONA
Sponsor: Aveni Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Lack of Funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-12-12
Primary completion date: 2023-12-12
Completion date: 2024-07-12
Plan to share individual participant data: NO
Clinical trial NCT03132155: QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
Official title: A Phase 2 Study of AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma That Contains the Ewing Sarcoma Breakpoint Region 1-activating Transcription Factor-1 (EWSR1-ATF1) Gene Fusion
Sponsor: NantPharma, LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Prematurely terminated due to lack of therapeutic effect
Enrollment: 8.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-29
Primary completion date: 2021-08-13
Completion date: 2021-09-21
Limitations and caveats: The study was terminated early due to low enrollment. Only the safety data is provided.
Plan to share individual participant data: NO
Clinical trial NCT04554459: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph+ ALL
Official title: Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia
Acronym: Pona-CELL
Sponsor: Institute of Hematology and Blood Transfusion, Czech Republic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: slower recruitment rate;
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-16
Primary completion date: 2023-09-01
Completion date: 2024-07-01
Plan to share individual participant data: NO
Clinical trial NCT05542446: Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation
Official title: Pharmacokinetics of Colistin in Critically Ill Patients With Extracorporeal Membrane Oxygenation
Acronym: COL-ECMO2022
Sponsor: St. Anne's University Hospital Brno, Czech Republic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: After agreement between sponsor and investigator, insufficient patients recruitment
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-09-01
Primary completion date: 2024-01-19
Completion date: 2024-01-19
Plan to share individual participant data: NO
Clinical trial NCT04636567: Open-label Study to Evaluate Nerindocianine as a Surgical Aid in Ureter Delineation During Minimally Invasive Surgery
Official title: A Phase 2 Open-label Study to Evaluate the Use of Nerindocianine as a Surgical Aid in the Delineation of Abdominopelvic Ureter Anatomy Via Near-infrared Fluorescence Imaging in the Setting of Minimally Invasive Surgery
Sponsor: Li-Cor, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Clinical program has been suspended for business reasons.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-03-31
Primary completion date: 2021-07-31
Completion date: 2021-12-31
Plan to share individual participant data: NO
IPD sharing description: There is no plan to make individual participant data (IPD) available.
Clinical trial NCT04365660: 18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma
Official title: A Phase 2 Study of 18F FTC 146 PET/CT in Patients With Newly Diagnosed Osteosarcoma
Sponsor: Stanford University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: lack of accrual with no intent of continuing
Enrollment: 1.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-01-28
Primary completion date: 2021-05-28
Completion date: 2021-07-22
Plan to share individual participant data: NO
Clinical trial NCT04634604: A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
Official title: A Randomized Trial of Low-Dose Bevacizumab Versus Laser for Type 1 Retinopathy of Prematurity
Acronym: ROP3
Sponsor: Jaeb Center for Health Research (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Lack of feasibility to recruit.
Enrollment: 16.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-04-27
Primary completion date: 2023-08-14
Completion date: 2023-08-14
Limitations and caveats: Early termination leading to small numbers of subjects which precluded statistical analysis. Active participants were released from study at time of study termination.
Plan to share individual participant data: YES
IPD sharing description: Yes In accordance with the NIH data sharing policy, a de-identified database is placed in the public domain on the Pediatric Eye Disease Investigator Group (PEDIG) public website after the completion of each protocol and publication of the primary manuscript.
IPD time frame: Data will be made available after publication of each primary manuscript.
IPD access criteria: Users accessing the data must enter an email address.
Clinical trial NCT03043313: Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer
Official title: MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 117.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-06-23
Primary completion date: 2022-03-28
Completion date: 2023-11-02
Baseline population: The Full Analysis Set includes all subjects who were enrolled and received any amount of study treatment and had HER2+ tumors as defined by one or more protocol required local tests.
Clinical trial NCT04365231: Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial
Official title: Efficacy Evaluation of Hydroxychloroquine Azithromycin in the Treatment of COVID-19 in Pregnant Women: an Open-label Randomized Clinical Trial
Acronym: HASCOPT
Sponsor: Hospital St. Joseph, Marseille, France (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: WITHDRAWN 
Why stopped: no authorization obtained
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-04-01
Primary completion date: 2020-06-01
Completion date: 2021-04-01
Plan to share individual participant data: NO
Clinical trial NCT02954991: Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Official title: A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer
Sponsor: Mirati Therapeutics Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: This study was terminated as a result of Sponsor portfolio reprioritization.
Enrollment: 161.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-11-07
Primary completion date: 2021-11-04
Completion date: 2021-11-04
Baseline population: The Safety Population was defined as all participants who received at least 1 dose of any study treatment (sitravatinib, glesatinib, or nivolumab). 1 participant has been excluded from the analysis as the PD-L1 status could not be confirmed due to a missing laboratory sample.
Limitations and caveats: Enrollment into glesatinib cohorts was discontinued in November 2017 as a result of Sponsor portfolio reprioritization. The analysis and reporting of this treatment arm is limited and will be summarized for selected tables only.
Plan to share individual participant data: NO
Clinical trial NCT05152303: A Study of Remimazolam Tosilate for Sedation in the ICU
Official title: Efficacy and Safety of Remimazolam Tosilate for Injection for Sedation in the Intensive Care Unit (ICU) - a Multicenter, Randomized, Single Blind, Dose Finding Phase II Clinical Trial
Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 60.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-10-12
Primary completion date: 2023-04-02
Completion date: 2023-04-19
Plan to share individual participant data: UNDECIDED
Clinical trial NCT02274155: Anti-OX40 Antibody in Head and Neck Cancer Patients
Official title: Phase Ib Study of a Monoclonal Antibody to OX40 (MEDI6469) Administered Prior to Definitive Surgical Resection Patients With Locoregionally Advanced, Oral Head and Neck Squamous Cell Carcinoma
Sponsor: Providence Health & Services (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 3.0
Start date: 2014-11-12
Primary completion date: 2017-09-17
Completion date: 2023-12-21
Plan to share individual participant data: NO
Clinical trial NCT04423068: Inpatient Adolescent Contraception
Official title: Intervention to Facilitate Contraception Provision by Pediatric Hospitalists: A Feasibility Study
Sponsor: Children's Mercy Hospital Kansas City (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: COMPLETED 
Enrollment: 25.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-12-10
Primary completion date: 2022-04-01
Completion date: 2023-04-04
Plan to share individual participant data: NO
Clinical trial NCT03599518: DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
Official title: A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Gefitinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Sponsor: Daiichi Sankyo (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was terminated based on a business decision by the Sponsor.
Enrollment: 20.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-09-21
Primary completion date: 2020-04-22
Completion date: 2020-06-29
Baseline population: Demographic and baseline characteristics were assessed in the Full Analysis Set.
Limitations and caveats: The sponsor decided to terminate the study at the end of the Dose Escalation part and the Dose Expansion part was not conducted.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/
IPD time frame: Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.
IPD access criteria: Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.
Clinical trial NCT02830594: Pembrolizumab and Palliative Radiation Therapy in Treating Patients With Metastatic Esophagus, Stomach, or Gastroesophageal Junction Cancer
Official title: Combining Pembrolizumab and Palliative Radiotherapy in Gastroesophageal Cancer to Enhance Anti-Tumor T Cell Response and Augment the Abscopal Effect
Sponsor: City of Hope Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 14.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-10-05
Primary completion date: 2022-01-20
Completion date: 2024-01-16